(Article by UDaily staff)
The University of Delaware has entered into a Collaborative Research and Development Agreement with the U.S. Food and Drug Administration on behalf of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
A part of the Manufacturing USA network, the institute has more than 120 partners, including private companies, academic institutions and nonprofits, and will open headquarters in 2020 at UD’s STAR Campus.
According to the agreement, the FDA and NIIMBL have the ability to collaborate in a pre-competitive environment to strengthen research, innovation, training and collaboration in the biopharmaceutical manufacturing industry.
“We are increasingly seeing the potential for advanced manufacturing innovations that can improve drug quality, help address shortages of medicines, speed time-to-market, and support personalized medicine through technologies including 3D printing and continuous manufacturing,” said Acting FDA Commissioner Dr. Ned Sharpless.
NIIMBL’s new headquarters will open in spring 2020 in the Ammon-Pinizzotto Biopharmaceutical Innovation Center now under construction on UD’s STAR Campus. The center will house NIIMBL, the Delaware Biotechnology Institute, and UD’s biomedical engineering program, as well as research laboratories in pharmaceutical discovery and molecular and medical sciences.
Click here for the full story from UDaily.